Remove 2007 Remove Cannabinoids Remove Clinical Trials Remove Data
article thumbnail

Marijuana and HIV: Much More Than Palliative Aid

Greencamp

Even though cannabis and cannabinoid-derived pharmaceuticals are both frequently used by HIV/AIDS patients, several studies show that something interesting happens when cannabis is consumed. 2007 ( 6 ). What is HIV and how is it manifested? Human immunodeficiency virus (HIV), as the name implies, harms the immune system. 2016 ( 3 ).

Marijuana 110
article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

At the same time, the outlook on cannabis research data is largely positive. The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Data collection. 2016 ; Sznitman et al. years (Atakan 2012 ).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety 45
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.

article thumbnail

Israel’s Tikun Olam Making Moves in the U.S. and Canada

Freedom Leaf

Tikun Olam , which was founded in 2007, controls nearly 40% of the Israeli medical-marijuana market. We’re also continuing to do some other clinical trials in Israel, specifically with our strains.” Although it’s a little bit observational, we’re able to understand with empirical data what strains are assisting them.